AOD-9604 for fat loss: the evidence

AOD-9604 is a 16-amino-acid fragment of human growth hormone that was engineered in the 1990s to do one job: burn fat without the rest of growth hormone's baggage. It reached human obesity trials, generated a lot of marketing copy, and was then quietly abandoned as a weight-loss drug when the numbers came in soft. This review walks through what the peptide actually is, what the studies really found, and where the evidence is strong, weak, or simply missing.

What AOD-9604 is

AOD-9604 stands for "Anti-Obesity Drug 9604." It is a synthetic copy of the tail end of human growth hormone (hGH) — specifically the region covering amino acids 176 to 191 — with one extra tyrosine added to the front to make the molecule more stable. Researchers at Monash University in Australia identified this C-terminal region as the part of growth hormone that drives fat breakdown, and they tried to bottle that single effect. The early metabolic characterization of this synthetic lipolytic domain was published around 2000 and laid the groundwork for everything that followed (Ng et al., synthetic lipolytic domain AOD9604, Horm Res 2000).

The whole point of the design was selectivity. Full-length growth hormone breaks down fat, but it also raises insulin-like growth factor 1 (IGF-1), can push blood sugar up, and can drive tissue growth. AOD-9604 was built to keep the fat-burning action while dropping those other effects. In the lab, that separation appears to hold up — the fragment does not meaningfully raise IGF-1 and has not shown the glucose problems linked to full hGH.

That is the theory. The harder question is whether any of it produces real fat loss in real people, and that is where the story gets complicated. To answer it fairly, it helps to separate three very different bodies of evidence: what happens in a dish, what happens in mice, and what happens in people. The peptide looks best in the dish, decent in mice, and disappointing in people — and that descending staircase is the single most important fact about AOD-9604.

How AOD-9604 is supposed to work

The proposed mechanism has two parts: speed up fat breakdown (lipolysis) and slow down fat storage (lipogenesis).

In animal and cell studies, AOD-9604 increased the rate at which fat cells release stored fat to be burned for energy. It also appeared to reduce the activity of enzymes that build new fat. The peptide is thought to work in part through the beta-3 adrenergic receptor, a switch on fat cells that, when activated, ramps up fat burning and raises energy use.

Here is an important nuance most marketing pages skip. A 2001 mouse study tested AOD-9604 in normal obese mice and in mice genetically engineered to lack the beta-3 receptor. The fragment still increased fat oxidation in the knockout mice, which means it does not depend entirely on that receptor — its full mechanism is not as clean or as understood as the "beta-3 fat-burning peptide" pitch suggests (Heffernan et al., 2001, Endocrinology). The honest summary: the peptide does something to fat metabolism in animals, but the exact pathway in humans is not nailed down.

A separate 2001 mouse study reinforced the upside in animals. Chronically treated obese mice given either growth hormone or the modified C-terminal fragment showed increased fat oxidation and weight loss (Heffernan et al., 2001, Int J Obes). So in rodents, the fat-burning signal is real and reproducible. The trouble is that rodent fat metabolism is not human fat metabolism, and many obesity compounds that shine in mice fizzle in people. AOD-9604 turned out to be one of them.

It is also worth naming what the mechanism is NOT. AOD-9604 does not suppress appetite. Unlike the GLP-1 class, which works largely by making people eat less, AOD-9604's pitch is purely metabolic — push fat cells to release and oxidize fat. That sounds elegant, but appetite suppression is exactly why the GLP-1 drugs produce the large, durable losses that AOD-9604 never did. A purely lipolytic peptide with no effect on how much you eat has a much harder path to real-world weight change.

Mechanism at a glance

Claimed action	Evidence type	How solid it is
Increases lipolysis (fat breakdown)	Cell and animal studies	Moderate — consistent in rodents
Inhibits lipogenesis (fat storage)	Cell and animal studies	Moderate — mostly preclinical
Works via beta-3 receptor	Mouse studies	Mixed — effect persists without the receptor
Does NOT raise IGF-1	Animal and human safety studies	Strong — repeatedly shown
Does NOT worsen blood sugar	Animal and human safety studies	Strong in short-term data
Produces meaningful human fat loss	Human trials	Weak — see evidence section

The actual human evidence

This is the section that matters most, and it is where the gap between hype and data is widest.

Early oral dosing study

One of the first human-relevant findings came from a 2000 study testing whether an oral form of the growth hormone fragment could change lipid metabolism. It showed effects on fat metabolism markers and helped justify moving forward (Heffernan et al., 2000, Am J Physiol Endocrinol Metab). This was early, mechanism-focused work — not proof of weight loss.

The pivotal obesity trial

The most cited human result is a 12-week, randomized, double-blind, placebo-controlled trial run by Metabolic Pharmaceuticals, the company developing the drug. It enrolled hundreds of obese adults across several oral dose levels. In the early phase, lower-dose groups showed modest weight loss versus placebo — figures commonly reported land around 2 to 3 kg of additional loss over 12 weeks.

But here is the critical part the supplement pages bury: the larger, definitive trial failed to hit its primary endpoint. When Metabolic Pharmaceuticals ran the bigger confirmatory study, AOD-9604 did not produce weight loss meaningfully better than placebo at the doses tested. The company reported to shareholders in 2007 that the peptide showed no real promise as a weight-loss drug and dropped that program. Development as an anti-obesity medicine effectively ended there.

A second honesty flag: the strongest-sounding obesity efficacy numbers were generated and reported by the company that owned the drug, and the full results of the pivotal failed trial were never published in a peer-reviewed journal in the way a positive result would have been. That is a textbook pattern of industry-funded, incompletely published data. Treat the rosy 2-3 kg figure as a best case from an early subgroup, not as established fact.

What the safety record does show

Where the human data is genuinely reassuring is safety, not efficacy. Across trials, AOD-9604 did not raise IGF-1, did not impair glucose tolerance, and did not produce a notable adverse signal at the doses studied. It was well tolerated. The problem was never that it hurt people — it was that it did not work well enough to justify approval.

It is worth understanding why a drug that fails to work still gets a clean safety read. A compound that barely moves the needle on fat loss also, almost by definition, is not doing much else in the body. "Well tolerated" and "no measurable benefit" often travel together. So the reassuring safety profile is not the win it sounds like in marketing copy — it partly reflects how little the peptide does.

How to read industry-funded efficacy claims

Most of the glowing AOD-9604 numbers online trace back to the developer's own early-phase reporting, and a lot of it was communicated through investor updates and conference presentations rather than peer-reviewed journals. That matters for a few concrete reasons. Early-phase trials are small and prone to chance findings. Subgroup results — like a single low-dose arm looking good — are easy to highlight and easy to misread. And when a positive result is real and important, companies publish it loudly; when the definitive trial fails, the full data often never reaches a journal. AOD-9604 fits that pattern. The lesson is not that the researchers were dishonest, but that you should weight a published, replicated, placebo-controlled result far more heavily than a press-release figure.

Honest evidence grade

Claim	Best available evidence	Grade
Burns fat in test tubes and rodents	Multiple animal/cell studies	B (consistent preclinical)
Causes meaningful fat loss in humans	One early subgroup positive; pivotal trial failed	D (did not confirm)
Safe and well tolerated short term	Multiple human safety studies	B (good short-term safety)
Long-term safety in humans	No long-term human data	F (unknown)
Helps joints / osteoarthritis	Early animal work; injected into rabbit joints	D (very preliminary)
FDA-approved for fat loss	Not approved for any indication	Fails — not approved

The one-line takeaway: solid preclinical fat-burning, reassuring short-term safety, and no convincing proof it produces real weight loss in people. Companies do not abandon working obesity drugs in a market this large.

Dosing and how people use it

Because AOD-9604 is not an approved drug, there is no official dosing label. What follows describes how it has been studied and how clinics and research suppliers have used it — not a recommendation.

In trials, oral and injectable forms were both explored. In the body-composition crowd, the peptide is most often used as a daily subcutaneous injection, with commonly cited research-context doses around 250 to 500 micrograms per day, sometimes dosed in the morning on an empty stomach on the logic that lower insulin helps fat mobilization. Some protocols run 5 days on, 2 days off, in cycles of several weeks.

Parameter	Typical research-context use	Note
Route	Subcutaneous injection (oral studied)	Injection most common in practice
Daily amount	~250-500 mcg	No approved dose exists
Timing	Morning, fasted	Theory-based, not proven
Cycle	Often 4-12 weeks	Long-term human data absent
Stacking	Sometimes with CJC-1295/ipamorelin	Adds growth-hormone effects and risk

None of these numbers come from an FDA label or a positive confirmatory trial. They are convention, not evidence. If you want context on the broader category and how dosing is approached, see our growth hormone peptides guide and the peptide reconstitution guide.

How it compares to alternatives

The honest comparison is unflattering for AOD-9604, because the fat-loss field moved on dramatically.

AOD-9604 vs other options

Option	Strength of fat-loss evidence	Notes
AOD-9604	Weak in humans	Failed pivotal obesity trial
GLP-1 drugs (semaglutide, etc.)	Strong, FDA-approved	12-15%+ body weight loss in trials
Triple agonists (retatrutide)	Very strong in trials	Largest losses reported to date
Sermorelin / ipamorelin (GH peptides)	Weak for direct fat loss	Raise GH/IGF-1, different risk profile
Diet + resistance training	Strong, free, durable	The actual foundation

If the goal is real, measured fat loss, the modern GLP-1 and dual/triple-agonist drugs are in a completely different league, backed by large published trials. For a sense of where that science is heading, see our reviews of semaglutide's mechanism of action and the retatrutide triple-agonist Phase 2 results. Against those, AOD-9604 is a peptide that was tried for the same job and did not clear the bar.

Legal status and sport

This is where AOD-9604 gets genuinely confusing, and where the situation changed in 2026.

It is not an FDA-approved drug. AOD-9604 is not approved to treat obesity or anything else in the United States. It did receive a "Generally Recognized as Safe" (GRAS) self-affirmation for use as a food/supplement ingredient years ago, but that is a safety designation for food use — it is not approval as a weight-loss medicine and says nothing about whether it works.

Compounding status shifted in 2026. The FDA had placed AOD-9604 and several other peptides into "Category 2" of its 503A bulk drug substances list — a designation that effectively blocked compounding pharmacies from making it. After legal challenges, the FDA moved AOD-9604 and several peptides out of Category 2 in April 2026, and its Pharmacy Compounding Advisory Committee is scheduled to formally review these peptides at a July 2026 meeting. So the regulatory picture is in motion, not settled. Anyone buying it should check the current status rather than trust a dated blog post (FDA, bulk drug substances under 503A). For more on this fast-moving area, see our peptide legality guide for 2026.

It is banned in sport. AOD-9604 is a growth hormone fragment and falls under category S2 of the World Anti-Doping Agency (WADA) Prohibited List. It is prohibited at all times and is detectable by anti-doping labs (WADA Prohibited List). Any tested athlete using it risks a positive result.

One technical point that has come up in sport science: AOD-9604 does not interfere with the standard WADA growth-hormone isoform immunoassay, so using it will not mask or trigger a false reading on the main hGH test — but the peptide itself is separately detectable by targeted methods (Orlovius et al., Drug Test Anal 2013). For athletes, the bottom line is simple: it is banned, it is findable, and there is no clever workaround.

The other claimed uses: joints and cartilage

Once the obesity program stalled, AOD-9604 got a second life in marketing as a joint and cartilage peptide, sometimes bundled with hyaluronic acid. The evidence here is even thinner than the fat-loss evidence. The main support is preclinical: a rabbit osteoarthritis study tested AOD-9604 injected into the joint, with and without hyaluronic acid, and reported some cartilage-protective effects (Kwon et al., AOD9604 in rabbit osteoarthritis, Ann Clin Lab Sci 2015).

That is a single animal study, not human evidence. There are no published human trials showing AOD-9604 repairs joints or treats osteoarthritis. So when a clinic markets it for "joint health," understand that the claim rests on rabbit cartilage and theory, not on people. For broader context on which peptides actually have joint and tendon data, see our roundup of the best peptides for joint and tendon recovery. If you want to scan the full body of indexed research yourself, the PubMed search for AOD9604 returns the complete published record — and it is a short list dominated by preclinical and analytical-chemistry papers, not large human trials.

Safety

The short-term safety record is one of the few clearly positive things about AOD-9604.

In human studies, it did not raise IGF-1, did not impair glucose handling, and did not produce a worrying side-effect signal. The most commonly reported effects were mild and injection-related — redness, irritation, or soreness at the injection site — plus occasional headache or mild stomach upset. Because it does not push IGF-1, it avoids the theoretical growth-related concerns tied to full growth hormone.

The big caveats:

No long-term human safety data exist. Trials were short, mostly around 12 weeks. What happens over months or years is unknown.
Product quality is a wild card. Most AOD-9604 sold online is "research chemical" grade with no guarantee of purity, dose accuracy, or sterility. Contamination and underdosing are real risks. See our notes on peptide vendor quality standards.
No approved manufacturing oversight. Without FDA approval, there is no standardized product you can trust by default.

So the safety summary is: looks benign in short human trials, but "benign and useless" is not the same as "safe to use long term."

Who it's for

Being blunt: based on the evidence, AOD-9604 is not a good bet for someone whose main goal is losing weight. The drug was tested for exactly that purpose by the company that owned it, and it failed to beat placebo convincingly enough to bring to market.

Who might still consider it, with eyes open:

People in research or experimental-protocol settings who understand they are using an unproven compound.
People who have already exhausted proven options and are working with a knowledgeable clinician who monitors them.

Who should skip it:

Anyone expecting GLP-1-level results — the data does not support it.
Tested athletes — it is banned and detectable.
Anyone who wants an approved, quality-controlled product — it does not exist.

For most people chasing fat loss, the boring answer wins: a calorie deficit, resistance training, sleep, and — if medically appropriate and supervised — one of the proven, approved weight-loss medications.

Questions to ask before trying it

If someone is offering you AOD-9604 and you are still considering it, a few direct questions cut through the marketing fast:

"Show me the human trial where it beat placebo." There isn't a published, confirmatory one for weight loss. If a clinic can't produce it, that tells you something.
"Is this a compounded prescription or a research chemical?" The quality, purity, and legality differ enormously. Research-grade vials carry real contamination and dosing risk.
"What's the current FDA compounding status this month?" Because the rules shifted in 2026 and are under active review, a confident, dated answer is a red flag.
"What proven option am I skipping to take this?" If the honest comparison is against an approved GLP-1 drug, the opportunity cost is steep.

A good clinician will not oversell a peptide that failed its main trial. If the pitch leans on "growth hormone benefits without the side effects" and skips the part where it did not produce meaningful weight loss, treat that as a sales script, not a medical recommendation.

Frequently Asked Questions

Does AOD-9604 actually cause fat loss?

In test tubes and rodents, it reliably increases fat breakdown. In humans, the evidence is weak. An early subgroup showed modest weight loss, but the pivotal confirmatory trial failed to beat placebo, and the developer abandoned it as a weight-loss drug. There is no convincing human proof of meaningful fat loss.

Is AOD-9604 FDA-approved?

No. It is not approved to treat obesity or any condition. It has a food-ingredient GRAS self-affirmation, which is a food-safety designation, not drug approval and not evidence that it works. Its compounding status changed in 2026 and is still under FDA review.

Does AOD-9604 raise IGF-1 or hurt blood sugar like growth hormone?

No, and this is its main design success. Across studies it did not meaningfully raise IGF-1 or impair glucose tolerance, which separates it from full-length growth hormone. The catch is that it also did not produce the weight loss that would make those advantages matter.

Is AOD-9604 banned in sports?

Yes. As a growth hormone fragment it is prohibited under WADA category S2 at all times, and labs can detect it. Tested athletes should avoid it entirely.

How does AOD-9604 compare to semaglutide or retatrutide?

It is not close. GLP-1 drugs like semaglutide and triple agonists like retatrutide produce large, well-documented weight loss in big published trials. AOD-9604 was tried for the same job and failed its key trial. The modern drugs are far better supported by evidence.

Medical disclaimer: This article is for educational purposes only and is not medical advice. AOD-9604 is not an FDA-approved treatment. Talk to a qualified healthcare provider before starting any peptide or weight-loss therapy.